The pharmaceutical company Noramco, headquartered on the Wilmington riverfront, has signed a letter of intent with Teewinot Life Sciences to produce pharmaceutical-grade cannabinoids, the chemical compounds in cannabis flowers and a component of marijuana.
Noramco specializes in producing active pharmaceutical ingredients, or biologically active materials, from controlled substances. The agreement gives Noramco access to Tweewinot’s proprietary CannSynthesis process, which produces pure cannabinoids through biocatalysis.
The goal is to provide a source for large quantities of “cannabinoid-based reference materials” outside of plant extraction, according to Jeffrey M. Korentur, president and CEO of Tweewinot Life Sciences.
Noramco plans to use the process to enter the growing market surrounding cannabis and cannabis-derived products.